Newsroom

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported positive initial Phase 1b clinical trial results for ALN-HTT02, an investigational RNAi therapeutic in development for the treatment of Huntington’s disease, which will be developed under the International Nonproprietary Name (INN) brezosiran (bre-ZOH-sir-an). The data were presented in oral and poster presentations at the European Huntington’s Disease Network (...

MADRID, Spain & ESPOO, Finland--(BUSINESS WIRE)--Telefónica and IQM Quantum Computers, a global leader in superconducting quantum computing, have joined forces to deploy the first quantum computer in the Community of Madrid. The initiative will strengthen the region’s scientific and technological capabilities, while driving the development of real-world cases for companies across the Community of Madrid. The IQM Spark quantum computer, an all-in-one solution specifically designed for research,...

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Teachers Insurance and Annuity Association of America/TIAA-CREF Investment Management, LLC/ Nuveen Asset Management, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle...

MADRID--(BUSINESS WIRE)--Genialis Supermodel shows how biology-first AI can extract meaningful insights from limited patient data, across clinical cohorts or a single patient....

BOSTON & BRISBANE, Australia--(BUSINESS WIRE)--AdvanCell Presents Updated Phase 1 Results on ADVC001 at ESMO 2026 with Encouraging Long-term Data...

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 22 October 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 22 October 2026 Number of Public Shares Purchased: 28...

LONDON--(BUSINESS WIRE)--  This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain. 23 October 2026 OBERON AIM VCT PLC (the “Company”) Issue of Equity and Total Voting Rights The Company announced on 23 March...

CAMBRIDGE, England--(BUSINESS WIRE)--Mundipharma hat heute zusätzliche Ergebnisse aus der globalen klinischen Phase-III-Studie ReSPECT bekannt gegeben, in der REZZAYO® (Rezafunginacetat) zur Prophylaxe invasiver Pilzerkrankungen (IFD) bei erwachsenen Patienten untersucht wurde, die sich einer allogenen hämatopoetischen Stammzelltransplantation (allo-HSZT) unterziehen. Die Ergebnisse der Phase-III-Studie wurden heute im Rahmen eines Late-Breaking-Vortrags auf der IDWeek 2026 präsentiert. Die Prä...

CAMBRIDGE, Inglaterra--(BUSINESS WIRE)--Mundipharma anunció nuevos resultados del ensayo clínico internacional de fase III ReSPECT, que evalúa REZZAYO® (acetato de rezafungina) para prevenir las infecciones fúngicas invasivas (IFI) en adultos sometidos a un trasplante alogénico de células madre hematopoyéticas (alo-TCMH). Los resultados se presentaron en una comunicación oral de última hora durante IDWeek 2026. La presentación amplía la información sobre los principales resultados de ReSPECT, a...

CAMBRIDGE, Inghilterra--(BUSINESS WIRE)--Mundipharma oggi ha annunciato ulteriori risultati dello studio clinico globale di fase III ReSPECT, che ha valutato REZZAYO® (rezafungina acetato) per la profilassi delle infezioni fungine invasive in pazienti adulti sottoposti a trapianto allogenico di cellule staminali ematopoietiche (allo-HSCT). I risultati di fase III sono stati presentati oggi in una comunicazione orale “late-breaking” all’IDWeek 2026. La presentazione fornisce ulteriori dettagli d...